Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Evaluation of a new flow cytometry crossmatch procedure for simultaneous detection of cytotoxicity and antibody binding.

Alheim M, Paul PK, Hauzenberger DM, Wikström AC.

Tissue Antigens. 2013 Aug;82(2):125-30. doi: 10.1111/tan.12151. Epub 2013 Jun 17.

PMID:
23772862
2.
3.

Improved flow cytometry based cytotoxicity and binding assay for clinical antibody HLA crossmatching.

Alheim M, Paul PK, Hauzenberger DM, Wikström AC.

Hum Immunol. 2015 Nov;76(11):849-57. doi: 10.1016/j.humimm.2015.09.047. Epub 2015 Sep 30.

PMID:
26429307
4.

Cytotoxicity and antibody binding by flow cytometry: a single assay to simultaneously assess two parameters.

Saw CL, Bray RA, Gebel HM.

Cytometry B Clin Cytom. 2008 Sep;74(5):287-94. doi: 10.1002/cyto.b.20424.

5.

Detection of complement-fixing and non-fixing antibodies specific for endothelial precursor cells and lymphocytes using flow cytometry.

AlMahri A, Holgersson J, Alheim M.

Tissue Antigens. 2012 Nov;80(5):404-15. doi: 10.1111/j.1399-0039.2012.01954.x. Epub 2012 Aug 30.

PMID:
22931381
6.

Flow cytometry-based cytotoxicity and antibody binding assay.

Alheim M.

Curr Protoc Cytom. 2013 Oct 9;66:Unit 6.34.. doi: 10.1002/0471142956.cy0634s66.

PMID:
24510725
7.

Cytotoxic flow cytometric crossmatch in renal transplantation: a single assay to simultaneously detect antibody binding and cytotoxicity.

Thammanichanond D, Athimang W, Paisooksantivatana K, Mongkolsuk T, Ingsathit A, Worawichawong S, Kitpoka P, Jirasiritham S, Kantachuvesiri S.

Transplant Proc. 2012 Jan;44(1):62-5. doi: 10.1016/j.transproceed.2011.11.024.

PMID:
22310580
8.

Positive B-cell only flow cytometric crossmatch: implications for renal transplantation.

Delgado JC, Eckels DD.

Exp Mol Pathol. 2008 Aug;85(1):59-63. doi: 10.1016/j.yexmp.2008.03.009. Epub 2008 Apr 10. Review.

PMID:
18499103
9.

Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch.

Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S, Pochinco D, Birk P, Nickerson P.

J Am Soc Nephrol. 2001 Dec;12(12):2807-14.

10.

[C4d]FlowPRA screening--a specific assay for selective detection of complement-activating anti-HLA alloantibodies.

Wahrmann M, Exner M, Haidbauer B, Schillinger M, Regele H, Körmöczi G, Böhmig GA.

Hum Immunol. 2005 May;66(5):526-34. Epub 2005 Feb 12.

PMID:
15935890
11.

Luminex-based virtual crossmatching for renal transplantation in South Africa.

Worsley CM, Mayne ES, Suchard MS.

S Afr Med J. 2011 Dec 14;102(1):40-3.

PMID:
22273137
12.

Clinical implications of flow cytometry crossmatch with T or B cells in living donor liver transplantation.

Takakura K, Kiuchi T, Kasahara M, Uryuhara K, Uemoto S, Inomata Y, Tanaka K.

Clin Transplant. 2001 Oct;15(5):309-16.

PMID:
11678956
13.

Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.

Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G.

Transplantation. 2013 Jan 15;95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc.

PMID:
23238534
14.
15.

Modified flow cytometry crossmatch detecting alloantibody-related cytotoxicity as a way to distinguish lytic antibodies from harmless in allosensitised kidney recipients.

Zieliński M, Zielińska H, Moszkowska G, Dȩbska-Ślizień A, Rutkowski B, Trzonkowski P.

Transplant Proc. 2013 Jan-Feb;45(1):88-94. doi: 10.1016/j.transproceed.2012.10.029.

PMID:
23375279
16.

Protective anti-donor IgM production after crossmatch positive liver-kidney transplantation.

McAlister CC, Gao ZH, McAlister VC, Gupta R, Wright JR Jr, MacDonald AS, Peltekian K.

Liver Transpl. 2004 Feb;10(2):315-9.

17.

Sensitization and sensitivity: defining the unsensitized patient.

Gebel HM, Bray RA.

Transplantation. 2000 Apr 15;69(7):1370-4.

PMID:
10798756
18.

Clinical cytometry and progress in HLA antibody detection.

Bray RA, Tarsitani C, Gebel HM, Lee JH.

Methods Cell Biol. 2011;103:285-310. doi: 10.1016/B978-0-12-385493-3.00012-7. Review.

PMID:
21722808
19.

The clinical importance of flow cytometry crossmatch in the context of CDC crossmatch results.

Graff RJ, Buchanan PM, Dzebisashvili N, Schnitzler MA, Tuttle-Newhall J, Xiao H, Schadde E, Gheorghian A, Lentine KL.

Transplant Proc. 2010 Nov;42(9):3471-4. doi: 10.1016/j.transproceed.2010.06.025.

PMID:
21094799
20.

Improved flow cytometric detection of donor-specific HLA class II antibodies by heat inactivation.

Ta M, Scornik JC.

Transplantation. 2002 May 27;73(10):1611-4.

PMID:
12042648

Supplemental Content

Support Center